<SEC-DOCUMENT>0001070081-20-000094.txt : 20200430
<SEC-HEADER>0001070081-20-000094.hdr.sgml : 20200430
<ACCEPTANCE-DATETIME>20200430160454
ACCESSION NUMBER:		0001070081-20-000094
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200430
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200430
DATE AS OF CHANGE:		20200430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		20835601

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8k43020q1.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:C21DE6D24A545E8992DEA0AD1ED9DFBD,x:03ac1115d8454fc0bc51f5683178181f-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:ptct="http://www.ptcbio.com/20200430" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="D2020Q2Earnings" name="dei:AmendmentFlag" id="Fact-A9E3CF0D2E3551CA856EF875753C150D-wk-Fact-A9E3CF0D2E3551CA856EF875753C150D" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="D2020Q2Earnings" name="dei:EntityCentralIndexKey" id="Fact-0F316B0A3D855A75A8D95B1C53259E17-wk-Fact-0F316B0A3D855A75A8D95B1C53259E17">0001070081</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ptct-20200430.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="D2020Q2Earnings">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-30</xbrli:startDate>
			<xbrli:endDate>2020-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context></ix:resources></ix:header></div><div><a id="s2255C486BF5C5824A69B25FAC00CE388"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d14734965e67-wk-Fact-A4392C3C24F65BFBB5203524D1CF196D" name="dei:DocumentType" contextRef="D2020Q2Earnings"><span style="font-size:18pt;font-weight:bold;">8-K</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d14734965e81-wk-Fact-D6DF5A267EB2515C94D21A0BB0051FD3" name="dei:DocumentPeriodEndDate" contextRef="D2020Q2Earnings" format="ixt:datemonthdayyearen">April 30, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span><ix:nonNumeric id="d14734965e86-wk-Fact-C7F8B9F609F4574CA20E6F0AC61FBAA3" name="dei:EntityRegistrantName" contextRef="D2020Q2Earnings"><span style="font-size:18pt;font-weight:bold;">PTC THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exact Name of Company as Specified in Charter)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d14734965e110-wk-Fact-CD6CB82CA2EB5BCF88E864F5F3E5CC39" name="dei:EntityIncorporationStateCountryCode" contextRef="D2020Q2Earnings" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d14734965e120-wk-Fact-4FF244FC34305995A48E05CC317BCD41" name="dei:EntityFileNumber" contextRef="D2020Q2Earnings">001-35969</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d14734965e130-wk-Fact-1FD3A078F92E52B5B28014A9452C8895" name="dei:EntityTaxIdentificationNumber" contextRef="D2020Q2Earnings">04-3416587</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Incorporation)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Commission</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">File Number)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(IRS Employer</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:141px;"></td><td style="width:114px;"></td><td style="width:33px;"></td><td style="width:228px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d14734965e182-wk-Fact-811B3C7B89EE5D8E8475D0B9FFCEEEEC" name="dei:EntityAddressAddressLine1" contextRef="D2020Q2Earnings">100 Corporate Court</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d14734965e203-wk-Fact-9F584A880CC35439896AF6986E8BB23D" name="dei:EntityAddressCityOrTown" contextRef="D2020Q2Earnings">South Plainfield,</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d14734965e208-wk-Fact-04642572F78A50059C16B056EA59F3C4" name="dei:EntityAddressStateOrProvince" contextRef="D2020Q2Earnings">NJ</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d14734965e218-wk-Fact-B1F8EA9F77AC50799C2D8F838E4A40D7" name="dei:EntityAddressPostalZipCode" contextRef="D2020Q2Earnings">07080</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Zip Code)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d14734965e245-wk-Fact-E0750D6B47285152A7DED1D0C66A2DCB" name="dei:CityAreaCode" contextRef="D2020Q2Earnings">(908)</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d14734965e249-wk-Fact-A0798484872A5CE7871AD5B5B8D0A688" name="dei:LocalPhoneNumber" contextRef="D2020Q2Earnings"><span style="font-weight:bold;">222-7000</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Not applicable</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">see</span><span style="font-family:inherit;font-size:10pt;"> General Instruction A.2. below):</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d14734965e270-wk-Fact-0B45DD57E74453DF9C6B8A5209F79DC8" name="dei:WrittenCommunications" contextRef="D2020Q2Earnings" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d14734965e280-wk-Fact-8DB5F855FF0D5D5DA2E221F97C61E7C5" name="dei:SolicitingMaterial" contextRef="D2020Q2Earnings" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d14734965e290-wk-Fact-2CFEFEBC1040529C8CC746A9D4967463" name="dei:PreCommencementTenderOffer" contextRef="D2020Q2Earnings" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d14734965e300-wk-Fact-06660543BCAF50719AA6DFD46452C418" name="dei:PreCommencementIssuerTenderOffer" contextRef="D2020Q2Earnings" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:18%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d14734965e342-wk-Fact-D6995E07B3915450AE17EB24D731FC2A" name="dei:Security12bTitle" contextRef="D2020Q2Earnings">Common Stock, $0.001 par value per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d14734965e347-wk-Fact-DA967A09486D5DCFBBA9B5D48B391688" name="dei:TradingSymbol" contextRef="D2020Q2Earnings">PTCT</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d14734965e352-wk-Fact-09B608EB4F525B7DB2EAD9D76F58BB61" name="dei:SecurityExchangeName" contextRef="D2020Q2Earnings" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d14734965e362-wk-Fact-F600E61B292154458BD1C6D1EA986CC3" name="dei:EntityEmergingGrowthCompany" contextRef="D2020Q2Earnings" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;  </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s70176FA199BB5CB3B9EDD6026F34CFC7"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02. &#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 30, 2020, PTC Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended March 31, 2020. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this Item 2.02.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01. Regulation FD Disclosure.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company will host a conference call on April 30, 2020 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended March 31, 2020, as well as other corporate highlights and updates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Directions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the&#160;Securities Act of 1933, as amended, or the&#160;Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01. </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(d) Exhibits</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:6%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ptct2020q1earningsrele.htm"><span style="font-family:inherit;font-size:10pt;">Press Release, dated April 30, 2020 issued by PTC Therapeutics, Inc.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:6%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: April 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Emily Hill</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emily Hill</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ptct2020q1earningsrele.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFE8E39990E5A7D78638ECC5CBEFA97E8"></a></div><div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">EXHIBIT 99.1</font></div><div style="line-height:120%;text-align:left;"><img src="ptct2020q1_image1a01.gif" alt="ptct2020q1_image1a01.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">PTC Therapeutics Reports First Quarter 2020 Financial Results </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:12pt;font-weight:bold;">and Provides a Corporate Update</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-style:italic;">- Risdiplam demonstrated clinically meaningful and statistically significant results across broadest population of spinal muscular atrophy (SMA) patients studied to date; PDUFA date August 24, 2020 - </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-style:italic;">- PTC provides an update on clinical and regulatory programs -</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#333333;font-style:italic;">- First quarter 2020 total revenues were</font><font style="font-family:Arial;font-size:11pt;font-style:italic;">&#32;$68.3 million, 27% year over year growth -</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">SOUTH PLAINFIELD, N.J., April 30, 2020 </font><font style="font-family:Arial;font-size:11pt;">&#8211; PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2020. </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#8220;PTC continued to execute on our strategic priorities including the development and commercial fronts in the first quarter highlighted by DMD franchise revenue growth and strong risdiplam results,&#8221; said Stuart Peltz, Ph.D., CEO of PTC Therapeutics. &#8220;The breadth of positive clinical risdiplam data reinforces the global commercial competitive profile of this therapy, which has the potential to be the first and only at-home SMA treatment, a critical advantage in the COVID-19 environment. We look forward to a number of potential value-creating catalysts including the risdiplam PDUFA date, and multiple clinical milestones in the upcoming months.&#8221; </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Key First Quarter and Other Corporate Updates: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;background-color:#ffffff;color:#333333;">Total net product revenues were</font><font style="font-family:Arial;font-size:11pt;background-color:#ffffff;">&#32;$68.2 million across our commercial portfolio in the first quarter of 2020 representing 28% year over year growth. Translarna</font><font style="font-family:Arial;font-size:11pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:7pt">&#8482; </sup></font><font style="font-family:Arial;font-size:11pt;background-color:#ffffff;">(ataluren) net product revenues were $40.5 million for the first quarter of 2020 and Emflaza</font><font style="font-family:Arial;font-size:11pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:7pt">&#174;</sup></font><font style="font-family:Arial;font-size:11pt;background-color:#ffffff;">&#32;(deflazacort) net product revenues were $27.5 million for the first quarter of 2020.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">PTC announced the appointments of Matthew Klein, M.D., to Chief Development Officer and Eric Pauwels to Chief Business Officer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Due to the uncertainty of the duration and severity of the COVID-19 impact, PTC is withdrawing financial guidance for the 2020 fiscal year.</font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#160;</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Compelling Data Across Patients with Type 1, 2 &amp; 3 SMA </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The FIREFISH Part 2 data in type 1 Spinal muscular atrophy (SMA) patients demonstrated achievement of motor milestones and motor function improvements not observed in natural history. The study met its primary endpoint (p&lt;0.0001), with 12 of 41 patients sitting, and all of its key secondary endpoints. Safety data was consistent with the known safety profile. There were no new safety signals and risdiplam was generally well tolerated. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The clinical data from Part 2 of the pivotal SUNFISH study evaluating risdiplam in people aged 2-25 years with non-ambulatory type 2 and type 3 SMA demonstrated statistically </font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptct2020q1_image1a01.gif" alt="ptct2020q1_image1a01.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:138%;padding-left:48px;text-align:left;"><font style="font-family:Arial;font-size:11pt;">significant results in primary and key secondary endpoints. Safety for risdiplam was consistent with its known safety profile and no new safety signals were identified.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Risdiplam clinical studies are ongoing, including RAINBOWFISH and JEWELFISH. When necessary, patients are receiving drug through contactless home delivery to ensure study compliance. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Earlier this year, Roche opened early access programs in the United States (U.S.) and European countries for type 1 SMA patients. Recently, Roche announced that the program will be expanded to include patients with type 2 SMA in countries where applicable, at the moment of filing of the regulatory application for risdiplam. In addition, in response to requests received as well as to the unique pressures of the COVID-19 pandemic, Roche has decided to amend the programs for type 1 and type 2 patients whose current treatment have been interrupted as a direct consequence of the COVID-19 pandemic. The Prescription Drug User Fee Act (PDUFA) date for risdiplam is now August 24, 2020, following the submission of additional data including SUNFISH Part 2. </font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Advancing Gene Therapy Platform </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">PTC now expects to file the biologics license application (BLA) submission with the U.S. Food and Drug Administration (FDA) in the second half of 2020 for its gene therapy program for Aromatic L-amino acid decarboxylase (AADC) deficiency. The study of the use of the commercial cannula in young patients has been delayed due to COVID-19.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The Marketing Authorization Application (MAA) process in the European Union (EU) for the AADC deficiency program is ongoing and PTC expects to receive the Committee for Medicinal Products for Human Use (CHMP) final opinion by the end of 2020.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:14pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:14pt;"><font style="font-family:Arial;font-size:11pt;">For our Friedreich ataxia (FA) and Angelman syndrome gene therapy programs</font><font style="font-family:inherit;font-size:14pt;">, </font><font style="font-family:Arial;font-size:11pt;">COVID-19 has impacted multiple investigational new drug application (IND) enabling activities. Therefore, we now anticipate the IND filings will be delayed by at least one quarter and we will provide an update on timing as we better understand the impact of COVID-19.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Due to COVID-19, PTC has deferred certain capital expenditures related to our leased biologics facility in Hopewell Township, New Jersey and now anticipates that GMP manufacturing of clinical material at this facility will begin in early 2021.</font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Updates in PTC's Diverse Product Pipeline</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">PTC now anticipates results from the U.S. Translarna dystrophin study in the third quarter of 2020.</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:Arial;font-size:11pt;">Due to COVID-19, the study site is currently closed to elective procedures, which includes those required to complete the dystrophin study.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The Huntington disease program remains on track to be in healthy volunteers prior to the end of 2020. A development candidate has been chosen and IND toxicology studies are ongoing. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">PTC now expects to initiate potential registrational trials in its Bio-e platform with PTC743 in refractory mitochondrial epilepsy in the third quarter of 2020 and in Friedreich </font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptct2020q1_image1a01.gif" alt="ptct2020q1_image1a01.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:138%;padding-left:48px;text-align:left;"><font style="font-family:Arial;font-size:11pt;">ataxia in the fourth quarter of 2020. The initiation of these studies has been delayed due to COVID-19.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The Phase 1 trial of PTC857, which is being developed for GBA Parkinson&#8217;s disease, remains on track to start in the third quarter, with no current delays due to COVID-19.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In the interest of the health and safety of employees and guests, PTC has postponed the Analyst Day previously scheduled for mid-June. We plan to host virtual deep dives on our platforms throughout the year.</font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Financial Highlights: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;background-color:#ffffff;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;background-color:#ffffff;color:#333333;">Total revenues were</font><font style="font-family:Arial;font-size:11pt;background-color:#ffffff;">&#32;$68.3 million for the first quarter of 2020, compared to total revenues of $53.6 million for the first quarter of 2019. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Translarna net product revenues were $40.5 million for the first quarter of 2020, compared to $35.3 million for the first quarter of 2019. These results reflect an increase in net product sales in existing markets as well as continued geographic expansion into new territories.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Emflaza net product revenues were $27.5 million for the first quarter of 2020, compared to $17.8 million for the first quarter of 2019. These results reflect new patient growth driven in part by diagnostic and educational efforts as well as ongoing operational improvements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Generally accepted accounting principles in the United States (GAAP) research and development (R&amp;D) expenses were $90.1 million for the first quarter of 2020, compared to $52.6 million for the first quarter of 2019. The increase in R&amp;D expenses reflects costs associated with advancing the gene therapy and Bio-e platforms and increased investment in research programs as well as advancements of the clinical pipeline.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Non-GAAP R&amp;D expenses were $81.9 million for the first quarter of 2020, excluding $8.2 million in non-cash stock-based compensation expense, compared to $47.9 million for the first quarter of 2019, excluding $4.7 million in non-cash stock-based compensation expense. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">GAAP selling, general and administrative (SG&amp;A) expenses were $58.2 million for the first quarter of 2020, compared to $40.6 million for the first quarter of 2019, reflecting continued investment to support our commercial activities including our expanding commercial portfolio.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Non-GAAP SG&amp;A expenses were $51.2 million for the first quarter of 2020, excluding $7.0 million in non-cash stock-based compensation expense, compared to $36.0 million for the first quarter of 2019, excluding $4.6 million in non-cash stock-based compensation expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Change in the fair value of deferred and contingent consideration was $0.9 million for the first quarter of 2020, compared to $21.2 million for the first quarter of 2019. The change in fair value of deferred and contingent consideration is related to the fair valuation of potential future consideration to be paid to former equity holders of Agilis Biotherapeutics, Inc. (Agilis) in connection with PTC&#8217;s acquisition of Agilis, which closed in August 2018.</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptct2020q1_image1a01.gif" alt="ptct2020q1_image1a01.gif" style="height:94px;width:156px;"></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In discussions with certain former shareholders of Agilis, PTC has agreed to exchange their pro rata share of specific future cash milestone payments in the aggregate amount of $225 million for a mixture of cash and equity. Under this agreement, which the former shareholders and PTC entered into on April 29</font><font style="font-family:Arial;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:Arial;font-size:11pt;">, PTC has pre-paid 94% of time-based cash milestones due in August 2020, and has agreed to issue 2,821,176 shares of common stock in exchange for 94% of future cash milestones for the AADCd BLA approval by the FDA and the receipt of a Priority Review Voucher in connection with that approval.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Net loss was $112.7 million for the first quarter of 2020, compared to net loss of $72.1 million for the first quarter of 2019. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Cash, cash equivalents and marketable securities totaled $595.9 million at March 31, 2020, compared to $686.6 million at December 31, 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Shares issued and outstanding as of March 31, 2020 were 62,758,520.</font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Due to the uncertainty with respect to the duration, nature and extent of impacts of the COVID-19 pandemic and responsive measures relating thereto, we cannot be certain that the pandemic will not cause us to experience further delays to the timelines set forth above or other negative additional impacts. </font></div><div style="line-height:138%;text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Non-GAAP Financial Measures:</font></div><div style="line-height:138%;text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptct2020q1_image1a01.gif" alt="ptct2020q1_image1a01.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.46153846153845%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:63%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:3%;"></td></tr><tr><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(In thousands, except share and per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Revenues:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net product revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">68,196</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">53,054</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Collaboration and grant revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">529</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">68,259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">53,583</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Operating expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cost of product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,085</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,376</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Amortization of acquired intangible asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,949</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,077</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">90,107</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">52,566</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Selling, general and administrative (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">58,209</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">40,544</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Change in the fair value of deferred and contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">21,160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">161,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">122,723</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(92,991</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(69,140</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(5,642</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2,288</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(13,832</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(109</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Loss before income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(112,465</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(71,537</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(576</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(112,687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(72,113</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted-average shares outstanding:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Basic and diluted (in shares)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">62,389,158</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">55,855,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Net loss per share&#8212;basic and diluted (in dollars per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.81</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1.29</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(1) Research and development reconciliation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">GAAP research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">90,107</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">52,566</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Less: share-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">8,179</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-GAAP research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">81,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">47,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">(2) Selling, general and administrative reconciliation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">GAAP selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">58,209</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">40,544</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Less: share-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7,041</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,577</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Non-GAAP selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">51,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">35,967</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptct2020q1_image1a01.gif" alt="ptct2020q1_image1a01.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Summary Consolidated Balance Sheets</font></div><div style="padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands, except share data)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">March 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2019</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">595,859</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">686,563</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1,545,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1,623,782</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">314,574</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">313,859</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">10,406</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">11,657</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1,016,858</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1,029,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Total stockholders' equity (62,758,520 and 61,935,870 common shares issued and outstanding at March 31, 2020 and December 31, 2019 respectively)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">528,734</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">594,330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1,545,592</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">1,623,782</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Today's Conference Call and Webcast Reminder:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:11pt;">Today's conference call will take place at&#160;4:30 pm (ET)&#160;and can be access by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 8267466. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. The accompanying slide presentation will be posted on the investor relations section of the PTC website. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">About PTC Therapeutics, Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:11pt;">PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">For More Information:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Investors:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:11pt;">Alex Kane <br>+1 (908) 912-9643</font><font style="font-family:inherit;font-size:10pt;">&#32;<br>akane@ptcbio.com</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptct2020q1_image1a01.gif" alt="ptct2020q1_image1a01.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Media:</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Arial;font-size:11pt;">Jane Baj <br>+1 (908) 912-9167</font><font style="font-family:inherit;font-size:10pt;">&#32;<br>jbaj@ptcbio.com</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Forward Looking Statements: </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses and other matters; expectations with respect to the impacts of the COVID-19 pandemic and related response measures; expectations with respect to PTC's gene therapy platform, including any potential regulatory submissions and manufacturing capabilities; advancement of PTC's joint collaboration program in SMA, including any potential regulatory submissions, commercialization or royalty or milestone payments; PTC's expectations with respect to the licensing, regulatory submissions and commercialization of its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC's gene therapy platform, including any potential regulatory submissions and potential approvals, manufacturing capabilities and the potential financial impact and benefits of its leased biologics manufacturing facility and the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the COVID-19 pandemic and related response measures and their effects on PTC&#8217;s business, operations, clinical trials, potential regulatory submissions and approvals, and PTC&#8217;s collaborators, contract research organizations, suppliers and manufacturers; the enrollment, conduct, and results of studies under the SMA collaboration and events during, or as a result of, the studies that could delay or prevent further development under the program, including any potential regulatory submissions and potential commercialization with regards to risdiplam; PTC's ability to complete a dystrophin study necessary to support a re-submission of its Translarna NDA for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) to the FDA, and PTC's ability to perform any necessary additional clinical trials, non-clinical studies, and CMC assessments or analyses at significant cost; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="ptct2020q1_image1a01.gif" alt="ptct2020q1_image1a01.gif" style="height:94px;width:156px;"></div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC's ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; expectations with respect to the commercialization of Tegsedi and Waylivra; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of the lease agreement for its leased biologics manufacturing facility; PTC's ability to satisfy its obligations under the terms of the senior secured term loan facility with MidCap Financial; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra or risdiplam.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ptct-20200430.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ptcbio.com/20200430" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ptct="http://www.ptcbio.com/20200430" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200430_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200430_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200430_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200430_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CoverPageDocument" roleURI="http://www.ptcbio.com/role/CoverPageDocument">
        <link:definition>0001000 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="ptct_CoverpageAbstract" name="CoverpageAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>ptct-20200430_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200430.xsd#CoverPageDocument" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>ptct-20200430_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200430.xsd#CoverPageDocument" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ptct-20200430_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ptct_CoverpageAbstract_9F9EA1EE689BFAAE34CB12EB78562B6C_label_en-US" xlink:label="lab_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cover page [Abstract]</link:label>
    <link:label id="lab_ptct_CoverpageAbstract_9F9EA1EE689BFAAE34CB12EB78562B6C_documentation_en-US" xlink:label="lab_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">cover page [Abstract]</link:label>
    <link:loc xlink:href="ptct-20200430.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="lab_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C4517B94B84052FE32B512EB785B4079_terseLabel_en-US" xlink:label="lab_dei_DocumentType_32F2CE97294E5893A735957E115A99A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C4517B94B84052FE32B512EB785B4079_label_en-US" xlink:label="lab_dei_DocumentType_32F2CE97294E5893A735957E115A99A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_32F2CE97294E5893A735957E115A99A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_32F2CE97294E5893A735957E115A99A0" xlink:to="lab_dei_DocumentType_32F2CE97294E5893A735957E115A99A0" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_0E83231B49EC1FE81A3612EB785BBF36_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_120A964EE3E15F5CAE086053190D0E75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_0E83231B49EC1FE81A3612EB785BBF36_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_120A964EE3E15F5CAE086053190D0E75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_120A964EE3E15F5CAE086053190D0E75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_120A964EE3E15F5CAE086053190D0E75" xlink:to="lab_dei_DocumentPeriodEndDate_120A964EE3E15F5CAE086053190D0E75" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_C596222BA97ACDF1A10B12EB785B6491_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_A3FE4585762750A2B5DFCD238E1AE2A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_C596222BA97ACDF1A10B12EB785B6491_label_en-US" xlink:label="lab_dei_EntityRegistrantName_A3FE4585762750A2B5DFCD238E1AE2A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A3FE4585762750A2B5DFCD238E1AE2A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_A3FE4585762750A2B5DFCD238E1AE2A0" xlink:to="lab_dei_EntityRegistrantName_A3FE4585762750A2B5DFCD238E1AE2A0" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_F7E76C8EB6B2A429763012EB785A74D9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_7FAE22832B3D547F8760180B3A935EA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_F7E76C8EB6B2A429763012EB785A74D9_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_7FAE22832B3D547F8760180B3A935EA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7FAE22832B3D547F8760180B3A935EA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_7FAE22832B3D547F8760180B3A935EA0" xlink:to="lab_dei_EntityIncorporationStateCountryCode_7FAE22832B3D547F8760180B3A935EA0" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_E7EA6DB36C0F561D720212EB7B8131CB_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_B55DD9A9DCA95EF3984A816CA0D15DBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contained File Information, File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_E7EA6DB36C0F561D720212EB7B8131CB_label_en-US" xlink:label="lab_dei_EntityFileNumber_B55DD9A9DCA95EF3984A816CA0D15DBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_B55DD9A9DCA95EF3984A816CA0D15DBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_B55DD9A9DCA95EF3984A816CA0D15DBA" xlink:to="lab_dei_EntityFileNumber_B55DD9A9DCA95EF3984A816CA0D15DBA" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_E3123AAC3A41E48A1A9712EB785C4170_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_3F15D9E9BBEA56DB9935ECC67CBEC21A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_E3123AAC3A41E48A1A9712EB785C4170_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_3F15D9E9BBEA56DB9935ECC67CBEC21A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_3F15D9E9BBEA56DB9935ECC67CBEC21A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_3F15D9E9BBEA56DB9935ECC67CBEC21A" xlink:to="lab_dei_EntityTaxIdentificationNumber_3F15D9E9BBEA56DB9935ECC67CBEC21A" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_DDE7C637B1DE93E587D112EB785A5F77_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_3154CFE4699357CB84A39200EB1F09B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_DDE7C637B1DE93E587D112EB785A5F77_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_3154CFE4699357CB84A39200EB1F09B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_3154CFE4699357CB84A39200EB1F09B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_3154CFE4699357CB84A39200EB1F09B4" xlink:to="lab_dei_EntityAddressAddressLine1_3154CFE4699357CB84A39200EB1F09B4" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_592048EF44AAE536846012EB785C0C8F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_C935C60E7E845571A74CB01BD4C66459" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_592048EF44AAE536846012EB785C0C8F_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_C935C60E7E845571A74CB01BD4C66459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_C935C60E7E845571A74CB01BD4C66459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_C935C60E7E845571A74CB01BD4C66459" xlink:to="lab_dei_EntityAddressCityOrTown_C935C60E7E845571A74CB01BD4C66459" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_D134AAF98F8970CE5DA412EB785C86A7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_9F7ECE4402A45515AC7D12E0694D4095" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_D134AAF98F8970CE5DA412EB785C86A7_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_9F7ECE4402A45515AC7D12E0694D4095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_9F7ECE4402A45515AC7D12E0694D4095" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_9F7ECE4402A45515AC7D12E0694D4095" xlink:to="lab_dei_EntityAddressStateOrProvince_9F7ECE4402A45515AC7D12E0694D4095" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_3A88E27A4B92A3EB914412EB785C141A_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_C690570473C15B10AADD0A392E7890A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3A88E27A4B92A3EB914412EB785C141A_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_C690570473C15B10AADD0A392E7890A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_C690570473C15B10AADD0A392E7890A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_C690570473C15B10AADD0A392E7890A0" xlink:to="lab_dei_EntityAddressPostalZipCode_C690570473C15B10AADD0A392E7890A0" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_1AEC18E92172051E527C12EB785C731C_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_FC9F877447405D38B7350D187ACFD26B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_1AEC18E92172051E527C12EB785C731C_label_en-US" xlink:label="lab_dei_CityAreaCode_FC9F877447405D38B7350D187ACFD26B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_FC9F877447405D38B7350D187ACFD26B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_FC9F877447405D38B7350D187ACFD26B" xlink:to="lab_dei_CityAreaCode_FC9F877447405D38B7350D187ACFD26B" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_5A3B1F056BEACDAA3FC312EB785D41F0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_06EC39F019C7506EACEC65549FF8BB88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_5A3B1F056BEACDAA3FC312EB785D41F0_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_06EC39F019C7506EACEC65549FF8BB88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_06EC39F019C7506EACEC65549FF8BB88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_06EC39F019C7506EACEC65549FF8BB88" xlink:to="lab_dei_LocalPhoneNumber_06EC39F019C7506EACEC65549FF8BB88" xlink:type="arc" />
    <link:label id="lab_dei_WrittenCommunications_DCE23CB8DE201B588EA312EB785DBCD6_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications_DCEA24A2B89052B4B1C3D630BD5EC844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_DCE23CB8DE201B588EA312EB785DBCD6_label_en-US" xlink:label="lab_dei_WrittenCommunications_DCEA24A2B89052B4B1C3D630BD5EC844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_DCEA24A2B89052B4B1C3D630BD5EC844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_DCEA24A2B89052B4B1C3D630BD5EC844" xlink:to="lab_dei_WrittenCommunications_DCEA24A2B89052B4B1C3D630BD5EC844" xlink:type="arc" />
    <link:label id="lab_dei_SolicitingMaterial_760B757C59FA279516CD12EB785D2D23_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial_9B15F3C04C0B59CC9BAE0BB8AFBAFC59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_760B757C59FA279516CD12EB785D2D23_label_en-US" xlink:label="lab_dei_SolicitingMaterial_9B15F3C04C0B59CC9BAE0BB8AFBAFC59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_9B15F3C04C0B59CC9BAE0BB8AFBAFC59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_9B15F3C04C0B59CC9BAE0BB8AFBAFC59" xlink:to="lab_dei_SolicitingMaterial_9B15F3C04C0B59CC9BAE0BB8AFBAFC59" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementTenderOffer_344CB19EC791150E96E912EB785DB49A_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_17C516CBC64457FEB34BC7EA8583DA1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_344CB19EC791150E96E912EB785DB49A_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_17C516CBC64457FEB34BC7EA8583DA1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_17C516CBC64457FEB34BC7EA8583DA1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_17C516CBC64457FEB34BC7EA8583DA1A" xlink:to="lab_dei_PreCommencementTenderOffer_17C516CBC64457FEB34BC7EA8583DA1A" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_59137A62338E67AAB28C12EB785D6654_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_5FA85A9B86E5546EB917CC6ABC06AC94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_59137A62338E67AAB28C12EB785D6654_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_5FA85A9B86E5546EB917CC6ABC06AC94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_5FA85A9B86E5546EB917CC6ABC06AC94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_5FA85A9B86E5546EB917CC6ABC06AC94" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_5FA85A9B86E5546EB917CC6ABC06AC94" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_001777A8A6AF6538D2A412EB7859C521_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_95DB72F8B7B751C29672F4A035B5C111" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_001777A8A6AF6538D2A412EB7859C521_label_en-US" xlink:label="lab_dei_Security12bTitle_95DB72F8B7B751C29672F4A035B5C111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_95DB72F8B7B751C29672F4A035B5C111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_95DB72F8B7B751C29672F4A035B5C111" xlink:to="lab_dei_Security12bTitle_95DB72F8B7B751C29672F4A035B5C111" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_B80EC5FA2E5A9146AE5012EB785D4F73_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_0CBC1EFC2A2659368EBEBF864CE4A074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_B80EC5FA2E5A9146AE5012EB785D4F73_label_en-US" xlink:label="lab_dei_TradingSymbol_0CBC1EFC2A2659368EBEBF864CE4A074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_0CBC1EFC2A2659368EBEBF864CE4A074" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_0CBC1EFC2A2659368EBEBF864CE4A074" xlink:to="lab_dei_TradingSymbol_0CBC1EFC2A2659368EBEBF864CE4A074" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_BD2611354DB294EA551E12EB785E1FBF_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_2E691D9D9CE15407AADF65B0C99E3861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_BD2611354DB294EA551E12EB785E1FBF_label_en-US" xlink:label="lab_dei_SecurityExchangeName_2E691D9D9CE15407AADF65B0C99E3861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_2E691D9D9CE15407AADF65B0C99E3861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_2E691D9D9CE15407AADF65B0C99E3861" xlink:to="lab_dei_SecurityExchangeName_2E691D9D9CE15407AADF65B0C99E3861" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_273F49BF87E829DB473712EB785EE2F6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_DE165A299D8F5D91A482F6B7D361C7B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_273F49BF87E829DB473712EB785EE2F6_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_DE165A299D8F5D91A482F6B7D361C7B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_DE165A299D8F5D91A482F6B7D361C7B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_DE165A299D8F5D91A482F6B7D361C7B8" xlink:to="lab_dei_EntityEmergingGrowthCompany_DE165A299D8F5D91A482F6B7D361C7B8" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_FB2DC3B7252F22BA459212EB785B3EDD_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_99D5626D294058A89E48BACFAC851D08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_FB2DC3B7252F22BA459212EB785B3EDD_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_99D5626D294058A89E48BACFAC851D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_99D5626D294058A89E48BACFAC851D08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_99D5626D294058A89E48BACFAC851D08" xlink:to="lab_dei_EntityCentralIndexKey_99D5626D294058A89E48BACFAC851D08" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_32233D09D70BAE14723212EB785B60EE_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_12152766B06256D7A459B2A459173A35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_32233D09D70BAE14723212EB785B60EE_label_en-US" xlink:label="lab_dei_AmendmentFlag_12152766B06256D7A459B2A459173A35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_12152766B06256D7A459B2A459173A35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_12152766B06256D7A459B2A459173A35" xlink:to="lab_dei_AmendmentFlag_12152766B06256D7A459B2A459173A35" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ptct-20200430_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200430.xsd#CoverPageDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:href="ptct-20200430.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_32F2CE97294E5893A735957E115A99A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_DocumentType_32F2CE97294E5893A735957E115A99A0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_120A964EE3E15F5CAE086053190D0E75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_DocumentPeriodEndDate_120A964EE3E15F5CAE086053190D0E75" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A3FE4585762750A2B5DFCD238E1AE2A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_EntityRegistrantName_A3FE4585762750A2B5DFCD238E1AE2A0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7FAE22832B3D547F8760180B3A935EA0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7FAE22832B3D547F8760180B3A935EA0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_B55DD9A9DCA95EF3984A816CA0D15DBA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_EntityFileNumber_B55DD9A9DCA95EF3984A816CA0D15DBA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_3F15D9E9BBEA56DB9935ECC67CBEC21A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_EntityTaxIdentificationNumber_3F15D9E9BBEA56DB9935ECC67CBEC21A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_3154CFE4699357CB84A39200EB1F09B4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_EntityAddressAddressLine1_3154CFE4699357CB84A39200EB1F09B4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_C935C60E7E845571A74CB01BD4C66459" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_EntityAddressCityOrTown_C935C60E7E845571A74CB01BD4C66459" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_9F7ECE4402A45515AC7D12E0694D4095" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_EntityAddressStateOrProvince_9F7ECE4402A45515AC7D12E0694D4095" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_C690570473C15B10AADD0A392E7890A0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_EntityAddressPostalZipCode_C690570473C15B10AADD0A392E7890A0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_FC9F877447405D38B7350D187ACFD26B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_CityAreaCode_FC9F877447405D38B7350D187ACFD26B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_06EC39F019C7506EACEC65549FF8BB88" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_LocalPhoneNumber_06EC39F019C7506EACEC65549FF8BB88" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_DCEA24A2B89052B4B1C3D630BD5EC844" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_WrittenCommunications_DCEA24A2B89052B4B1C3D630BD5EC844" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_9B15F3C04C0B59CC9BAE0BB8AFBAFC59" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_SolicitingMaterial_9B15F3C04C0B59CC9BAE0BB8AFBAFC59" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_17C516CBC64457FEB34BC7EA8583DA1A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_PreCommencementTenderOffer_17C516CBC64457FEB34BC7EA8583DA1A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_5FA85A9B86E5546EB917CC6ABC06AC94" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_5FA85A9B86E5546EB917CC6ABC06AC94" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_95DB72F8B7B751C29672F4A035B5C111" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_Security12bTitle_95DB72F8B7B751C29672F4A035B5C111" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_0CBC1EFC2A2659368EBEBF864CE4A074" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_TradingSymbol_0CBC1EFC2A2659368EBEBF864CE4A074" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_2E691D9D9CE15407AADF65B0C99E3861" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_SecurityExchangeName_2E691D9D9CE15407AADF65B0C99E3861" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_DE165A299D8F5D91A482F6B7D361C7B8" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_EntityEmergingGrowthCompany_DE165A299D8F5D91A482F6B7D361C7B8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_99D5626D294058A89E48BACFAC851D08" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_EntityCentralIndexKey_99D5626D294058A89E48BACFAC851D08" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_12152766B06256D7A459B2A459173A35" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_5AE72C9E4DEC5732840CC15955380EBB" xlink:to="loc_dei_AmendmentFlag_12152766B06256D7A459B2A459173A35" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ptct2020q1_image1a01.gif
<TEXT>
begin 644 ptct2020q1_image1a01.gif
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E,4455V2Q11=?A#%&&6>DL48;;\0Q1QUWY+%''W\$,DCZ @( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W$W;>V(/]Q\970=G"K[N07U!+ P04    " ":@)Y0F5R<(Q &  "<)P
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M9^TB8N_^E4SB[SF&SYK_ %!+ P04    " ":@)Y0_\ F"+T   "% @  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSK9)!"H,P$ "_(GE 5VWIH:BG
M7KRV_4#0U8B:A.R6ZN^;>E%!H0<O"6'#S$"2/+"3W!A-JK$4#'VG*16*V=X
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M7?S-R$=*[4%?#?_)\@M02P$"% ,4    " ":@)Y0'R// \     3 @  "P
M            @ $     7W)E;',O+G)E;'-02P$"% ,4    " ":@)Y0)^B'
M#H(   "Q    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+
M 0(4 Q0    ( )J GE"C)05[[@   "L"   1              "  9D!  !D
M;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( )J GE"97)PC$ 8  )PG   3
M              "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ FH">4+HQ,J^C @  EPL  !@              ( !]P@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( )J GE ;Z@'F8P(  . %   4
M              "  = +  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0
M   ( )J GE"ZH3F*UP$  #(&   -              "  64.  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ FH">4-O]Q#4] 0  , (   \
M ( !9Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( )J GE#_P"8(O0
M (4"   :              "  =$1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( )J GE +C]@#(0$  %<$   3              "
M <82  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     *  H @ (  !@4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639288096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CoverpageAbstract', window );"><strong>cover page [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 30,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Contained File Information, File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CoverpageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>cover page [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CoverpageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>12
<FILENAME>0001070081-20-000094-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-20-000094-xbrl.zip
M4$L#!!0    ( )J GE!5:"P;\!@  ,RD   .    83AK-#,P,C!Q,2YH=&WM
M/6MSVSB2GW=_!4Y[NY5461*?$JDDWJ+XF/'.Q/'9GIJM^T:1D,4-13(DY<?]
M^NL&28FR ,K.V+&2<5*)+34>W8U^ R#?__-V&9-KFA=1FGSHR0.I1V@2I&&4
M7'WH_7;I]8W>/X__^OZ_^OU_3\]_)4X:K)8T*8F=4[^D(;F)R@7Y/:3%9S+/
MTR7Y/<T_1]=^OU]URB:V(CONR%$T2]=TUS!-Q7$MR7)DUS$=;^H<W4XDU0]D
M6=9#0].U>2#- EV>ZR-#E<>&;,CS9K#-[$$]^ZH /.OIR;J9G69W>72U*(DB
M*5*#4@5?E$ OT)P4'WJ+LLPFP^'-S<W@1AVD^=50-DUS>(MM>E6C21$L:)A&
M_3D-D[2DZTYSOYBQ+F%4#.\U&BJ2;/8EN:_*S3#SHA\E)<UI4?*':#7@="_F
M63^:I;M=BW(YK(&";D57MX+?+0KZ11FNN]W.\GA0T&!PE5X/:R!VD^]U*[.\
MHU\-;?[A ,;V ,$JST'X[OJPQ.*![K?B$!!3G\]E '":!^4LYK='"*?#U<K/
M^1T0PNF0K_C-\Q6/_<@I/XX[^ C0YA^'CT!E(:2_$,A)$.>T0U(8F-,U\M.(
M/Q=">'.!GD0)!S\V4P7DK5&Z2LI\GVAL-\)AQMQA.KMSNC'M+ 1"50,Y2"=^
M%!3\N1B(AV @L#$ X+$_N19P/[D6(=3-PZTF' 2+?+OS9OURD3HRD<41NX6Z
M;M$AV.MFW5:F;M%A:1J#'46^8%';+3@DK8J^GP=Y&E..)+> G*YA$&2I8-8*
M)M":8L;1M$9K ,A'\\KWLRW&M]%L@+P9@WF_X"TS3LA@/"VE01SX<:"*[.D:
MSF,,C;JEI-6 VSW+:8!AP99G9R/@_(HDF<-Z78:;QMNJ(9Q[#>:H1"Y0V9RG
ML:@FY5W&DYLUB.=!*+0035.1Q[$- <>BU]8AX%GS+=\JY,7]5ET#[7?C?)NQ
M-0>LU@,P@5:<@?Q<P , <)K3VV#!GPLAG YID,T%WI:!.FCKIDEHOO>8;K'9
MYEJ!&L!UN6$TCT!)(#7H9W[.B5QWFO %GCMKIPK+'3HL4&#@0E^DB15,&(WP
M$%Q'(SQ$Z?(_ K^+$-X\@$"QRK) C!\#\^;ZLHK*.\%L#,;3_5L1 V45M#^.
M$HKYW 8]$5Z<L;,R*+=&AR]F43H(TN40$RY)4Z6U#(&]G0E\ 8)X](8BJX40
M3@=15L9-Q-"'=#H8OBY C#?C.,,Z_)OQ+-A"1,:"2P4.(\X-9SPI! <NCD"$
MX8<@<PEY>0L5&4_*-9[M^%OL/;8;\6Q5'7NE:7#3'9UA"T$8(@Y >-XU$RPN
M +BQ435]L5HNTEC0]5ZCCFA)Z0Z6%)[7*1=QY LTJP8*S!V]6HK-'0"[Z%VD
M>?D BIMF? R$L_.D-5J(0F6 </5;I$4(Z:!M/UD"BI+5DF]KPS(?8C@WA!8T
MCX*FPRU8W\_BZA-"[\?O]W.>G1A>7 N9"5S.C.=KL+C3G:AM&G J0!@B=>=G
M[18\/0P$V * UURDM5S)FV?]5=!9Y&!@GAE<"6H< .#[&*%_X46H&7]PGQ?.
MHI+F-.J(6!#*]R_+E!>*U1X&@8+ !4;D%6PV@16_9+,CYNTP3ATB>.87M#U3
MD(3S2."@-G!ND"GHQ&N\SAKV9SCBW#@4UE4K('\)YHM88+1K( _=/,C$,53&
MZ])DRD(];#7@!Q:"%+6!")C"+4<U3.&7I"I(&.4<.[_IB7"><2O2^5Q@WQ D
M2/"Z;5R[!<_U"FQ!1[6S@[HUG-,9L8HZ- C4KO23@-YW96E9++I=&;80F$BQ
M7%= GH *C#;79B=I\@"/">GD/:\)HE[,!):R@G'#AR+-!*:K@G%++7.*VD^%
MK*]ST'7#-8["/%F8'=<.7.C9!14D0=R_!G4$YWNKY_P"0D++??R )CM:O4>I
M>>R/$U'6P4"\#%"PQ"6/#TW(U!E/\>WBIC:^ITXHSFU 9H1L'*%$;?F8+O[Q
MN8>&O=/J"R@3&+6$:]3 $XMCB0;*<X#1_%J412.(G^B CMT*%+^!"OP*KQS4
ML(]?#@+<K[^(Z;K^(JSM<)*J366'EU0Q-],=*//72A0@\0.C!0U$&1>">*N4
M!J(P$2!<)\=Q )5WXR89N'O0%3WQ=Z6C)"C]6P'I#,:K566"XA  .FSDWN(%
M7[FC6XBH:+"EX$W/3=%M6.9^4LS3?,GJICB.WI>,+302@:.KF@NRMLX]^U:T
M)^]@S3=)^U!6^LJH%=L*DX0*QE,!D6^F7,>,FWL" @'"V>:+_"O1!@A >.+B
M"PJM . S7LAP#J/+2!0?-!!>=AA007B%D [_1E%0S](H$13^^>UXOD%@#;B5
M\8)7XF:*S2]NHYGKCL3Y2$4A+_YA2QORTY.JQ-Z9R59P@89UUD3X]9#;F*]8
M+'K_]Z^M0D].KU*!CV,@0; >Q**#%!60:^($Y;^J?,^O-W15&_@9ZQ45F3 &
MZTK,A+M][18\.:57>W9_ZRCUJKUM1$6E'9YKQ.'"<AN[>G1]6 %[QW_]R_L%
M]4/X^9?W2UKZ!%OW<:L&DF,[34HDX1+2G!X)JD\?>B6]+8?5N;,AZUA&94R/
MFP-O[X?59QAZ6(_]?I:&=\?OP^B:%.5=#$LTA\'Z<W\9Q7>3RVA)"W)*;\AY
MNO23=PQ61/]')[*4E>\ R79/H#>+_3O,S6CO^'UT.\%):%[]&H4A3=BO #^M
MLK(*\]OR',-9!W=]_D=Q_3R)DJNB1Q)_B:/2:&(!]B%2X,7^58]$L#J>'Y1]
MRW15VY,<Q55U7;8M0Q^YGC'6Q[IJR[KD]&\^]Q_4L$<JK_2A!VYL,DMAA?UD
M[L<%$,)^O!]N(?Z5=+@)+,"=C;;2CT^2D-[^0N]:]$B>*H^FDJ4ZAJY;8]TR
M'%.?RK:N*KKI0IS0T+.O8>]8DB19&DN2(>^@/MQ>CG7^61R_QVH:*P L?:"%
ML"KR9,&R#=ROZS<;<X/; D6?@3'5_M KHF46X[(/M\>HIFO/P3X6Z2IGGUAU
M8E+SCW'B/O^8(%?-*.,??M%\ V8:OIM'-"=L2LJ-FNR37[8Y<K\SFV-X?Y)Z
MC@S8EH;M68L2O*P#^G^,N/8EK:]*3?<-K-4!Q%?0O(&T$%C/UWQ1<Z=AY9IW
MPY:*@;6Y9GI\_-YG;"P41==MS1A-/=W6#46S1N94T3W+EB3;50T#U\K?ZMC2
M90S9^@N*QU\GLB+]?5?UWQ>9G_",1I1 -A65G!ZS? CS8;]FVM;D%7 O'ID?
MXJGB_BPMRW2)0]^NORO3K/H"N07.-+I*)@'%\[!M9(Q'HX\]V,>;"I%9&H<P
MQ&^G)Y>N0RXNK4OW8INN[X2""]?^[?SD\L2](-:I0]Q_VS];IS^YQ/[T\>/)
MQ<7)I]-O2=;7R16'K-^MBY]/3G^Z_'1Z1)R!/2"*I&OF=[E"WJ?SCZ3!O/I_
MV_.@JH>R-E8U<Z33T<9%6)IJ*K9J*YHWTJ?>=*HKDJHKFB/;GFR.G+9?:@*$
M5C@A<&8<FCKQ-_J_K/E^WPUMB/IC/"+?<F651Z^LPL<:-._</;TDY^[9I_/+
M[Y*$LU5>K/RD)&5*+FB .3V159+F1-;?A&]).B?E@B)H!0-&$$JZ$'O[R14E
M5E B6#95[?!-3.\8733B>TZS-"_)F^8S]<$_TZ(D]!HOE.0,3,.W$T*^0KY;
MV&WWNUE$)>W#-P$%%;K)_:S7;0<,>6T'G)'CZ98R&KO@_67=-C5'D2UI.H5D
M0_8<E6<'SE@$XE:A2;=!V J<0VB^A,:+T+^[ ][0I'=L97D4$U4Z8M=H1%9@
M^\>C>?9-38#17J;.51BM5\$>>\;4]$:2Z6GZ6+,M17)'GF39(]F;6I:ZFR6<
MTZNHP()9>0J0I[7*9Y<VN?S9/;?.W-\N3^R+(W)R:@]^+$/]M:K^QKV%!2/(
M=-1P.UW""'?$+\A%1@/,%D(2)<1>0)A/\[<O0%)KDJ9_3.?E9-T_2C"Q89_;
M6"2HJ?'NG#!DZ<]B2@(:QS7T0T_JL<]H=)K/CZ\0+/W\*DHJ]/Q5F39?L'MU
MU3<W45@N)J/Q&#"9I3DD,_T@C6,_*^BD^:7-%AR+H0Q)3QF"6B"*R8>>COE,
M&>)_^1K:V$\VAR)K%;6LV7VH/.H /EE7#G+7-"^CP(]K^BKQ>+>ULLH]46E_
MKL6I_57%7:6:MB4MWR;Z?H!AE&5I8QF=D3TU%+"([E2?VIYAN,9(\W1/=77;
M5LU=RWB2!&D.CI9M(ER4X'/L:C_%3L-'>"O<8\%LO:19GE[C).BN'!K[-^"Y
M]CFJ*GW=7O!OMY(I3#6/TYNZCO,4=N\??Y-'TKL#H>]P)%792*KF>8JF>;:J
MJ9)NFKJE&:Z$,BJ/I[:CR;N2ZD4QA7%G--_COR6L#^OFR'P5NU>Q0[%3-V*'
M0;HEC0W/5%Q= 1NI&)*L6::F*[9AF/JNV%WZMR=U:;.Z5/,P&=3ZJB:/=&/\
M<"%\47?6T:49]7DB1.9S,,W]A ='R+\@NRW"B.6_PG#PI9"%$';+7[X]$%7[
MT4W)BPDG)"S+J"@.41;1'9+*%KV*X0\NAB?G%\1=9G%Z1_.#$\1M[TA.TP%/
M'IES&[+4>&>_ZC7+_YHL7Y?_:):O[<WR94WN2M4[$WE5[4KD%4.0R*^Q4WI_
MYIC54-8QJR'+4]4>3PW3=74',GIMK#O2U/0\VX4_]F[,:H5A3HNB_O$K"+2\
M)UZ5)8G8=6!#X;=57KYF3W\6^@ZECL::O)3&*9*ZUCC3TPW-,@S)ME5=4TW#
M'%G>R#1&KC&=*JHCU#@;?OV47Z8WR1Y]NTA7Y8*<Q7Z4S",:AT>'K6TOMB;&
MYI26-M(4?:QX8\/2)4DW;3RTI8]<2S<]U=:$:\(2S$_Y69Y>1^QB4.?"G/[K
ML%?B1[=[!^.!%7DC>U/9,US+],9CR]:EL6G:BF-XAFJXFJ5)SE@H>V=I4?KQ
M_T;9_FKZL326C+U;NGRC_:/%3)#RU S$7<.S'/0VROR8N+<T6)71-26?YI!P
MT.(U\_V>UQCT@J!B'%Z^^&A:-@<,_O$W0Y''[PI2TIAFBS2A)&%5FB,"8ARO
M$!GBY]0'K0WIY \?;>FT89J^MF&N--8E9S35QHJAR[IBC1W7D1W)'HTLQ;&G
M;1N&88P%*#[ :KTQ)>/M'JOUQ^WU(T[M*9JY.;8'MMK0X.]8L73;'1MCV7+T
MJ3XU',D:&4:;YE]3T*0S7*\'%?AWB=K&6%&4_EB2I*<[![*/-8>K'ARL3].2
M^%D6@_D"#3]\$D#0O32'M:O/LN2D_EC[*5#N.1YC2:YH2"XPSB2_^D59GW%[
MQH,MK+;3+F%I6%AY GHY!\R_"[SM!0T^LZ.2(%]YFN415C1FZ2V94?#0N$X(
MQ.4C1O\7,H]BM,A10?!ASX!+B"<PBVBYBDL_H>FJB.](X9=1,;]C/>L.Z0SH
MJ$J>]=',?.T#R K&R0D>=:IA\S2&R;$?GH^(<$>A(&_^B!5@S2<1A)=1 &07
ME'ZU)R$_T83F$%^=)(#_JCI[:@V40<6RMY/#$(,]=G^\V>65IIKN./K8'6N:
MKCJ>:8^FD#4J$H3PIF-OV?W?@26P[KC3LTKJ(G;QR(,O>,=IYL,*ER!G'4)K
M@3#&Y#>8!APK^7C!PCP3D'SWM&[BGL-\6$^]ZDC^P&E;4C,3N-?F)LE:9YO/
M5S$ED,G7.G+O3#,>97XCCXGMG1-%E0;0\$",YQ[I,S;29SA3W3-TW?,D1X>_
MEN(JBNR98WLDNV-[ZXS!10KJ"Z0G5Q_!3*%XO(K>U\VZX219UJS<E3M9\_NR
MTA*]K3/T:\'3I$'5\ON0/7,C>XKMN9X[M65)DW3%M W;'FLCRW2@)?RR=33Z
M+*=H]? F(;NO@LXOA\1Z7^S[*H.B68&C_:#%TKUV4-;"OO)F]O9A$EFU_2YD
M4I5:WG@T&DFZIDYMR].EL6Q:ULCQ'&V$AZXTV>B0R9.B6-'\53)?0#)5VM?>
M! ^3S+KM<TOF<R2BK=BCBM]I#AE QKN,Q12UCN>!!8^(BO^L1Q1,<S"23'6L
M__T/G5-0]YY3T.2_BT\I&&)8N]^A[((^6]6%S1'2H#Z\.&&:C:($@U_BLRRJ
M2WC!@@2Q7Q0_;NGY<9S)?5:RO;A;0MLW![/E\-)\:>YT,8&AC6L .WFSB.";
MC3$]X ,'3U<=?$A(I"FM>Z2FJ;O2>*J:LJ[IDN7*>*54<\:J[-F*M94B5A[J
M3E9F3$OW%*8Q?()5N"C3X/,1^6]I($DRR?R<7/OQBI(,'^ZQ./@[.2^W2)M+
M_XX%.9,EF9HQ@BS>]J93RYSJCF;@JMW;/:BM1&4D]JS0V:5]^<I]+O?UC8I(
MYG0D&>Y4\W1%GXZ=J>):CNF,1YYN3*<CF:<B382Z_Y+O3J: %JRYMG;J%Z'_
MA?P4IY [0/P70P1(/OKY9_J(0W'?9 /S:<+BWO%)$F(J0,GLC@2L@ XAW6<P
MY91=RKA7W8X* N-#'H%1WQ6YRM.;<H$9159?[@WI'"AC5WNK<I^D<YY?L'EL
M@4K>X';W^!TK^36-81I8S@PO!N.&2Y66*+.^\L!G(:P'Q11ETZ\U[.#0$Y;>
ML<OG<G4Z8/?_A^^3JJ.-KGDC27)'\E0Q%7!'&BB8(]LC1W8MTQC9-N="?8/6
M3PRK^E[WCY.<'ZX\G,P[= ^/&' 5.=K9H5J FC+#!FJ:I"S17164M0*DZWTP
M?,)HQ)+?ZC%:N(1LKO@.)V<OFD653R!3!$A.KZ,"^H'R^TF B^8'[.FLV!B?
MBQ[Z>5A4.V"A*,M6W_CK++NMU0.1R.\OB_P.\^/"%)P;70]?\6?;4[W_N*Z7
M>W;8(M^4(*YH?Y93_W/?GX.IG/CQC7^'YQZ&BWS[T6AC20:G;,FF.9WJ]E2=
MFJ[CC"1EY*F:[=EC[/.#/AH-S5@?U"4'(SHI5DO0M;MGJ5*=E'1)E(&D#(A(
M#<YIL8I+=F#N$VAK7=<#G2/>6AWM%,P# A[A^)Y@03XE9/O!-4>$/30%FOL9
M74%06QSAQ<H!>8-:CR>H%.F=W7@Z^"2_>PND)&!+ @PK@,R-C<EKPM$V8?<O
M*_8P$5+9, C;(!M5Y6KB 4Y*YJLX)NP1B;6=R=A1PYSBNW@IA#?%J@I>P)TE
MM5UBMHZ=*JC18%54B"7F*_!OQ0(Z^!B&+*)95!+3',AHU5BT8;,WES1G03!%
M7A\^>,,:]"I([RU;+G82H;ED"L.")5\_\1'/*-2C;D3BT)V62)[' TD> %>N
M5G%UCL)SB!,509P6JYQ^6Q%%L6B>3G,3@7@LTJ(D>$8O:5@/F5>,B[<MRL0O
MB391)7+VD8#T@. EI(R6] C%(4./6)T@64OO@#@0M()#K")1'+1L34YO,Y"X
M H4'.X-C_3I)9_/?4!@=?K)G\I.U3)$%\"Y&_E4&8I7ALZ:*;\OQ1YXO>H(9
MG2BOE+G 95RD-\ADB%!0]Y&=]]?:SVE]9+.R!KN60JS[^ Z$,OW1.8I:$R7K
M9]!73 *I;I[LMCGPB@I?,'/%) Y5G_W29MI;+$P!WS$<G5%((L'&AHTWF$<Q
M#6M?P!0 @L<L+2AS>.O@T7A@:LBTPU]6BM-V.NW&C><YPMB6J= -A+>D6,W^
M@P4!9H@IP=?Z17$U%9L<#$)1X7,$I.0U45&;IB[[S@+J^HS9>N^M<O'\W+E-
M"T-UW;Y-S!'6:&E68F.P,2C&>*Z-ELA,<&V 15$]DBO81J=8@57Q:XP&Q ):
M;N@,T@)PA=791T#G*KJF.\L/J&P1BCH!3;;H11V;LX8;*4H39B]#!D1A:!_,
MFZ$'!JUEMP#PZ<B,XK0]$^-@@^.V>#;.L\+PJ3WG\^CPHW;Q=G#B(=ZUU4=V
M4>)MN(V5K<N]#Z[K UZ]1YFEG;W0IXL_3!9_/*;D"MB_VX/^MXB>-@$]N]N&
MD6C1MJ;W/?EN/?+P@L3>,3[DM"'@]4& 3[/_K@\,T]"^P0:\/!9OLH_$H/'X
M*_;?:TJ:%<]N29'&44C^)K$_S[TC\FQJW<1"I_?CQD/8!WHJ+?_J:VTOO.K/
M>!?&H4601]GN$Z]>8J^\9C,S8SL\_@:[A)@('(CT_WB7.K]N<06J[V\UY9X2
M 0>2YA,V@>=M5TMI9>S>]<CFC2A8M_@BTWK#")/LP:)<?@V?SUB:?EZEZ4<D
M9/G'O<)-7>:#=(1?C%RODO^2^O@-5$Z6M%>-^U[]Z24K7 $)!+=LR#Q/E_NJ
MSD?U3FQ9E;5.V"L%";Y3\'N_A\T[WPOC^^4J?\8[ID^UE.TW0%2[M5]645ZG
M=P^M:W&V><-5?$<"?X5;L^WZ3%5-*8 $ &!Y!*:9T84?S]$HXD#,DM<-L'JS
MP@(*&PZ2C$6: _+A,VX__*ER-5F2GCM)TSLRL0Z0:AS((>EO[!X.Y:DJSY9P
M[HE[#B3FN;_JC45YHOOB!Q4@O-+Z_+0>2@#_5&$#OE9H0NZ_&>@@EO@9J)W>
M37Y<XH;%D+C8A/P<Q?&AR>YK=O9H^O @^LO)ZY.6>[[BY/*K(/\P@LQN'OW
MEM=>1'3>.BE9/5\P?ZJ"R+.=[CF8L\-_:3ZP=Z#_]3U[<_KQ_P-02P,$%
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M!2F$7%RBW46!.>6MF-%"Q=^\7YQK+]WG5A%/L3=,3_X'4$L#!!0    ( )J
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M7T=;$BC&S!Y M.5-&(Z:6_KFH-0BE?UH:NM/T)(H&U_[U=<=1*??IN4L&P(
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M-9TW$1V/@YEDMV!"I>5("TN,U91C%!&@-:2"4AP!J]13)_-FB2W] Q[[O&Q
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M#>&A;"XWC4)&T+1,KA/BQ^^:C:,B-1XZ#QX%[%RK2PF"S3@(LX9I@,"SW^,
M_CPAT5>ZZLM(JWV+#Q_*!!KVH84*^RA-(..0CUD@QBHRB29X]&$\TN=A.&5C
MP2/ RD$:,J2N27@B3>*^-# ^.8 W,!#MN('[6AG#^EIQ6(6$Q2I.0XY8SM2
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MM3F\0KF$]W$!1!@Z8/EYI[9#[TW,_>S]'9QC=EV[)4"G),A^;-V[5M=Y=TF
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M>+#5U<.N9D5\A2TA^(S=161;O'XT5@GX6\#].>!GS'V-M^MWY^T"YNY7:ZM
M_&:GT,Y]$+^S'.*7++_Y+'\\XM'LI-(!E]J>-XJ<E)>.V@-ER0FA*A7<Y!XX
M1Y6VO7]?N[LE-,?2C3L*5.9 ^/EPEQFJG"MTG9MPGO&>%5 ,4JR-O=*$K?*)
M\91;W!@%K@:>=?Q7BI6J(Q5B*3:VTAO*4%*91;+@!&;[[9[=BQI%PI[IDA5A
MY+E2[D.[]KJ/69M9UM45N$$3V;;(6KU[EUS2=A5:E!CU_#'J+57?^2EM*G0[
MNK-J=B>!9@20<DW^9HE>/M0B.UK;80@()LA^K!73N#^86K W,0@?SP7)Y1]U
M97X:$XC^U(8&'&3R(30]I&/2QQBHH<Q.HS$?F^3P[@NUAC7OV"#%! DVJNQW
MW,%AJ]YIG/9$:2OFMESG^ASS35^4! ]LJ)PVF^$1\HV#)6ML[WO\YZP!.N0S
M&3W@@$_<[),GYK6H$,@>M'Z@( Q(8V:JS*V'K0 IHB#J&$Z[1XO++HV!YQH>
M0*M7W^]88A*KH+6O(FL-V7R%8Q!<.-?]0E:8G7R/F_0"]OI=#W</:07Z)-LQ
M]^:DQ[*=.;0I+R8&X>S<'N0^91_%I020^8]*?3Q(>H%*H-T36<.E4;8%@/=>
M)"S$8P;)MJK7&X68S3VLJRAK!B%IOW&W&&^9;-X.'CL&+/,LHJ$> FBQIP;A
M68.4J*4U-L)/W7T35,  C/5]^Z!=L/8!F^;O^+ABX7>ZG8+_"4^?  S2)0?V
M!V7-WE:PVR>K;TD-6R]-I0GM6G4;6NF<Y2(?V9!+I^'MM[M>^PX[SN\SG^N4
M?_ ,'U8Y]PT&=,.IPV13X(E$F,IVWV='$'OV[%![/!V,T)V!9/<4WWP,D;LA
MB XYPN#P6' SVU;J4G9:)(HV2^-1&BI!-SHSXF<G.V4-TJ9/?,KG>!Y':JSI
M'@LMZ:2A 1:P X:X*F W#;02D=(&<"M!)8=IP[Z"$>%&=OI!A+8ZCK%P/I";
MWD,N)]I\?J*W\U54>;AT5J1YYE;^<(U&[@J&I;$':B%3VA)T:P%=O<[*W5&$
MWJ#;@T]1%LS#:WNX-DD031SYWEZ9FK%RE-%DUG F#70N&):'2#H:V/9_R_,N
MABORB*UWAR2=K5BYK=6YB=%)7G:O8Y8W6?"3_/(OF" UVQ=6+D&I\J']96KL
M14Q?Z7V"QQ5R P^;[.P2=];E]&K]2Z)%%%BJS?KYR62'DGAWZ WG"@/#2QII
MDQ3FAY3SGBT>P+<Z6W-H>]8&GM;JB@#Z4T<P'.&0;LK5N&DA,FCFX*DLY'U3
M#3H=N9Q?9 @_^U/0P1-N8EC%(30Z]-P=F&:O'PBR\X8  :<X#NMP@H[$.Z*J
M[/U7)HE0R2.,I D=68!#&W_!TR #UCB[@:>K>+L1K$=B6]%X%!/NQ*=5R57
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M8T8G,ADQ32=52T.>B*DBB8%!;:!TBH_;N4!/Q9&@>*H@]1/,6-,4!BJ- CM
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M&\_>P9^A-<X^"E1DK.>3GU<_.&B#8Q2&Q:9=]V"640<R'YC'%/2GT<"+BC^
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M2P$"% ,4    " ":@)Y056@L&_ 8  #,I   #@              @ $
M83AK-#,P,C!Q,2YH=&U02P$"% ,4    " ":@)Y0?Z"1PZH#  !=$@  $0
M            @ $<&0  <'1C="TR,#(P,#0S,"YX<V102P$"% ,4    " ":
M@)Y042Q7ECP!  "  @  %0              @ 'U'   <'1C="TR,#(P,#0S
M,%]C86PN>&UL4$L! A0#%     @ FH">4(^[B.>B 0  T@4  !4
M     ( !9!X  '!T8W0M,C R,# T,S!?9&5F+GAM;%!+ 0(4 Q0    ( )J
MGE =T$[^M0L  &1G   5              "  3D@  !P=&-T+3(P,C P-#,P
M7VQA8BYX;6Q02P$"% ,4    " ":@)Y01O=.%90&  !U-0  %0
M    @ $A+   <'1C="TR,#(P,#0S,%]P<F4N>&UL4$L! A0#%     @ FH">
M4. ,>[H7*P  X.D! !H              ( !Z#(  '!T8W0R,#(P<3%E87)N
B:6YG<W)E;&4N:'1M4$L%!@     '  < SP$  #=>      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>a8k43020q1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptct-20200430.xsd" xlink:type="simple"/>
    <context id="D2020Q2Earnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="D2020Q2Earnings"
      id="Fact-A9E3CF0D2E3551CA856EF875753C150D-wk-Fact-A9E3CF0D2E3551CA856EF875753C150D">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="D2020Q2Earnings"
      id="Fact-0F316B0A3D855A75A8D95B1C53259E17-wk-Fact-0F316B0A3D855A75A8D95B1C53259E17">0001070081</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="D2020Q2Earnings"
      id="d14734965e67-wk-Fact-A4392C3C24F65BFBB5203524D1CF196D">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="D2020Q2Earnings"
      id="d14734965e81-wk-Fact-D6DF5A267EB2515C94D21A0BB0051FD3">2020-04-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="D2020Q2Earnings"
      id="d14734965e86-wk-Fact-C7F8B9F609F4574CA20E6F0AC61FBAA3">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="D2020Q2Earnings"
      id="d14734965e110-wk-Fact-CD6CB82CA2EB5BCF88E864F5F3E5CC39">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="D2020Q2Earnings"
      id="d14734965e120-wk-Fact-4FF244FC34305995A48E05CC317BCD41">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="D2020Q2Earnings"
      id="d14734965e130-wk-Fact-1FD3A078F92E52B5B28014A9452C8895">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="D2020Q2Earnings"
      id="d14734965e182-wk-Fact-811B3C7B89EE5D8E8475D0B9FFCEEEEC">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="D2020Q2Earnings"
      id="d14734965e203-wk-Fact-9F584A880CC35439896AF6986E8BB23D">South Plainfield,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="D2020Q2Earnings"
      id="d14734965e208-wk-Fact-04642572F78A50059C16B056EA59F3C4">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="D2020Q2Earnings"
      id="d14734965e218-wk-Fact-B1F8EA9F77AC50799C2D8F838E4A40D7">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="D2020Q2Earnings"
      id="d14734965e245-wk-Fact-E0750D6B47285152A7DED1D0C66A2DCB">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="D2020Q2Earnings"
      id="d14734965e249-wk-Fact-A0798484872A5CE7871AD5B5B8D0A688">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="D2020Q2Earnings"
      id="d14734965e270-wk-Fact-0B45DD57E74453DF9C6B8A5209F79DC8">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="D2020Q2Earnings"
      id="d14734965e280-wk-Fact-8DB5F855FF0D5D5DA2E221F97C61E7C5">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="D2020Q2Earnings"
      id="d14734965e290-wk-Fact-2CFEFEBC1040529C8CC746A9D4967463">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="D2020Q2Earnings"
      id="d14734965e300-wk-Fact-06660543BCAF50719AA6DFD46452C418">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="D2020Q2Earnings"
      id="d14734965e342-wk-Fact-D6995E07B3915450AE17EB24D731FC2A">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q2Earnings"
      id="d14734965e347-wk-Fact-DA967A09486D5DCFBBA9B5D48B391688">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q2Earnings"
      id="d14734965e352-wk-Fact-09B608EB4F525B7DB2EAD9D76F58BB61">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="D2020Q2Earnings"
      id="d14734965e362-wk-Fact-F600E61B292154458BD1C6D1EA986CC3">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="a8k43020q1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="a8k43020q1.htm">a8k43020q1.htm</File>
    <File>ptct-20200430.xsd</File>
    <File>ptct-20200430_cal.xml</File>
    <File>ptct-20200430_def.xml</File>
    <File>ptct-20200430_lab.xml</File>
    <File>ptct-20200430_pre.xml</File>
    <File>ptct2020q1earningsrele.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "a8k43020q1.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "ptct-20200430_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptct-20200430_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "a8k43020q1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptct-20200430_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptct-20200430_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ptct-20200430.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20200430",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a8k43020q1.htm",
      "contextRef": "D2020Q2Earnings",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page Document",
     "role": "http://www.ptcbio.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a8k43020q1.htm",
      "contextRef": "D2020Q2Earnings",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Contained File Information, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "ptct_CoverpageAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "cover page [Abstract]",
        "label": "cover page [Abstract]"
       }
      }
     },
     "localname": "CoverpageAbstract",
     "nsuri": "http://www.ptcbio.com/20200430",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
